Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women.
The use of slow or rapid, subcutaneous, IgG (SCIG) infusions in pregnant women with primary antibody deficiencies has been described earlier, though only in single-case reports. In this study, we have evaluated the effect of rapid, SCIG infusions during 11 pregnancies in nine women [six women with common variable immunodeficiency (CVID), two with IgG-subclass deficiencies, and one with combined IgA and IgG2 deficiency]. The weekly infusions were given by the women themselves at a dose of 100 mg/kg/week throughout the pregnancy. No adverse systemic reactions or pronounced, local tissue reactions were recorded during or after the more than 400 infusions. The 11 babies were healthy and were born after 38-42 weeks of uneventful gestation. The concentrations of maternal S-IgG at the time of delivery in the four women with CVID ranged from 6.0 to 8.3 g/L, with cord/maternal S-IgG ratios of 1.0-1.5. The IgG subclasses were transferred to the infants. The SCIG home-therapy regime was greatly appreciated by the women.
Gardulf
A
A
Department of Immunology, Microbiology and Pathology, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden. ann.gardulf@immunlab.hs.sll.se
Andersson
E
E
Lindqvist
M
M
Hansen
S
S
Gustafson
R
R
D000328:Adult; D017074:Common Variable Immunodeficiency / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000276:immunology; D007279:Injections, Subcutaneous; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy* / Q000276:immunology; D011256:Pregnancy Outcome
D007074:Immunoglobulin G